In this report, global hemostats market is projected to reach USD 4.5 billion by 2024 from USD 2.7 billion in 2016, at a CAGR of 6.6% in the forecast period 2017 to 2024.

Based on geography, the global hemostats market is segmented into 5 geographical regions, such as,

North America,
South America,
Europe,
Asia-Pacific,
MEA,
Rest Of the World

Global hemostats market competition by top players including -

Ethicon US LLC (U.S.) is dominating the hemostats market followed by Pfizer and C.R. Bard Inc., along with others such as
Baxter,
Vascular Solutions, Inc.,
B.Braun Melsungen,
3-D Matrix, Ltd.,
Resorba Medical GmbH (an Advanced Medical Solutions Group plc Company),
Anika Therapeutics, Inc.,
Arch Therapeutics Inc.,
Biom?Up SAS,
CryoLife, Inc.,
Gamma Therapeutics, Inc.,
Hemostasis, LLC,
MedTrade Products Limited, I
ntegra LifeSciences Corporation,
Medline Industries, Inc.,
HEMOTEC MEDICAL GMBH,
Stryker,
CSL Behring,
Mallinckrodt,
Equimedical, B.V.

The global hemostats market is segmented on the basis of type, application, distribution channel, and end user.

The global hemostats market is segmented into 5 major types, namely thrombin based hemostats, combination agents, oxidized regenerated cellulose based haemostats, gelatin based haemostats and collagen based haemostats.

On the basis of application, the market is segmented into surgery and wound closure.

On the basis of end users, the market is classified into hospitals, community healthcare, ambulatory centres and clinics. In 2017, the hospital segment is expected to dominate the market and is expected to continue this trend till 2024.